Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. Even more concerning, they may increase the risk of brain swelling and bleeding, sometimes without obvious symptoms.
Coffee doesn’t just energize—it actively reshapes the gut and mind. Researchers found that both caffeinated and decaf coffee altered gut bacteria in ways linked to better mood and lower stress. Decaf even improved learning and memory, while caffeine boosted focus and reduced anxiety. Together, they show coffee works through multiple pathways beyond just caffeine.
Mifepristone, involved in most abortions in the U.S., can now be distributed only in person and at clinics.
“No one's pulling the pieces together”: a conversation with medical students about preventive care education.
“Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
Scientists have discovered a way to help the brain clean itself of harmful Alzheimer’s plaques by activating its own support cells. By increasing a protein called Sox9, researchers were able to boost the activity of astrocytes, star shaped cells that help maintain brain health. In mice that already showed memory problems, this approach reduced plaque buildup and preserved cognitive function over t
Free-living amoebae are emerging as a global health concern, fueled by warming temperatures and outdated water systems. While many are harmless, some can cause deadly infections and even protect other dangerous microbes. Their ability to survive heat and disinfectants makes them especially hard to control. Scientists say improved surveillance and water treatment are urgently needed.
Scientists have uncovered a surprising link between simple body movement and brain health: every time you tighten your abdominal muscles—even slightly—your brain may gently sway inside your skull. This subtle motion, triggered by pressure changes in connected blood vessels, appears to help circulate cerebrospinal fluid around the brain, potentially flushing out harmful waste.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet-to-be-identified partner.
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions
Casey Means out as surgeon general nominee, America's renewed fertility anxiety, and more health news
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s disease.
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, Esperion Therapeutics is itself being acquired and taken private by healthcare investment firm ArchMmed.
The company looks to achieve an "amicable resolution as soon as possible" and is focused on minimizing disruption to its operations, a spokesperson said in an emailed statement.
A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF bispecific heads into the ASCO annual meeting with a prestigious spot on the plenary session.
Fierce's Angus Liu speaks with Ionis CEO Brett Monia about the science behind antisense oligonucleotides, what upcoming phase 3 readouts from Ionis’ Novartis-partnered lipoprotein(a) program and AstraZeneca-partnered ATTR cardiomyopathy program could show, and how the company is working to build a commercial biotech business.
Psychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions.
Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again.